MUC1 and neoplasm: In this study, we constructed a MUC1 aptamer-conjugated nanoparticle with S2.2 for delivery of paclitaxel to MUC1-positive tumor cells, combining the advantages of aptamer as targeting agent and the strengths of nanoparticle as drug carrier.